Inhalation therapy: Technological milestones in asthma treatment

Advanced Drug Delivery Reviews

Volumn 55, Issue 7, 2003, Pages 779-791

  Dalby, Richard ^a   Suman, Julie ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Next Breath LLC   (United States)

Author keywords

Aerosol technology; Dry powder inhalers; Metered dose inhalers; Nebulizers; Spacer

Indexed keywords

DISEASES; DOSIMETRY; DRUG PRODUCTS; PERSONNEL TRAINING;

PATIENT TRAINING;

RESPIRATORY THERAPY;

BENZALKONIUM CHLORIDE; CALCIUM CHLORIDE; CITRATE SODIUM; EDETATE DISODIUM; HYDROCHLORIC ACID; NITROGEN; POLYSORBATE 80; PROPELLANT; SODIUM CHLORIDE; SODIUM HYDROXIDE; SULFURIC ACID;

AQUEOUS SOLUTION; ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; DRY POWDER; HEALTH CARE PERSONNEL; HUMAN; INHALER; NEBULIZER; PATIENT COMPLIANCE; PRIORITY JOURNAL; TRAINING;

EID: 0038094385     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(03)00077-2     Document Type: Conference Paper

References (51)

1. C. Thiel, From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation, Respiratory Drug Delivery, V, Phoenix, Arizona, 1996.
2. I. Porush, G.L. Maison, Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine, (US Patent 2,868,691) US, 1959.
3. Dunbar C., Hickey A.J. A new millenium for inhaler technology. 21:1997;116-125.
4. USP24, <601 Aerosols, metered dose inhalers, and dry powder inhalers, (2000) 1895-1912.
5. P.R. Byron, Respiratory Drug Delivery, CRC Press, Boca Raton, FL, 1990.
6. McCullough J.R., Handley D.A., Jerrussi T.P., Rollins T.E., Kach P., DeGraw S.E., Munsey M., Kellerman D., Rubin P.D. The development of enantiomerically pure levalbuterol. Dalby R.N., Byron P.R., Farr S.J. Respir. Drug Delivery VI. 1998;113-118 Interpharm Press, Buffalo Grove, IL.
7. Rosenborg J., Borgstrom L., Jendbro M., Larsson P., Nyberg L. Long-acting beta-agonists: pharmacokinetic and dynamic insights conferred by altered routes of administration. Dalby R.N., Byron P.R., Farr S.J., Peart J. Respir. Drug Delivery VII. 2000;49-58 Serentec Press, Raleigh, NC.
8. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lothan N., Langer R. Large porous particles for pulmonary drug delivery. 276:1997;1868-1871.
9. Bot A.I., Tarara T.E., Smith D.J., Bot S.R., Woods C.M., Weers J.G. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. 17:2000;275-283.
10. Dellamary L.A., Tarara T.E., Smith D.J., Woelk C.H., Adractas A., Costello M.L., Gill H., Weers J.G. Hollow porous particles in metered dose inhalers. 17:2000;168-174.
11. Hirst P.H., Pitcairn G.R., Weers J.G., Tarara T.E., Clark A.R., Dellamary L.A., Hall G., Shorr J., Newman S.P. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. 19:2002;258-264.
12. Staniforth J.N. Performance-modifying influences in dry powder inhalation systems. 22:1995;346-353.
13. Staniforth J.N. Carrier Particles For Use in Dry Powder Inhalers. 2003;Vectura Limited, US.
14. Clay M.M., Pavia D., Newman S.P., Clarke S.W. Factors influencing the size distribution of aerosols from jet nebulizers. 38:1983;755-759.
15. Niven R.W. Atomization and nebulizers. Hickey A.J. Inhalation Aerosols. 94:1996;273-312 Marcel Dekker, New York.
16. Matthys H., Köhler D. Pulmonary deposition of aerosols by different mechanical devices. 48:1985;269-276.
17. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. 104:1999;S250-S252.
18. Moren F. Drug deposition of pressurized inhalation aerosols. Part 1. Influence of actuator tube design. Int. J. Pharm. 1:1978;205-212.
19. Salzman G.A., Pyszczynski D.R. Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with aerochamber. 81:1988;424-428.
20. Kim C.S., Eldridge M.A., Sackner M.A. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. 135:1987;157-164.
21. Lee H., Evans H.E. Evaluation of inhalation aids of metered dose inhalers in asthmatic children. 91:1987;366-369.
22. Berlinski A., Waldrep J.C. Metering performance of several metered-dose inhalers with different spacers/holding chambers. 14:2001;427-432.
23. W. Wilkes, J. Fink, R. Dhand, Selecting an accessory device with a metered-dose inhaler variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler, 14 (2001) 351-360.
24. Clarke J.R., Aston H., Silverman M. Delivery of salbutamol by metered dose inhaler and valved spacer to wheezy infants: effect on bronchial responsiveness. 69:1993;125-129.
25. Intal Cromolyn Sodium A Monograph. 1973;Fisons Corporation, Bedford, MA. p. 140.
26. Dunbar C.A., Hickey A.J., Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. 16:1998;7-44.
27. S.P. Newman, F. Moren, G.K. Crompton, A new concept in inhalation therapy, Amsterdam, Medicom 1987.
28. Hickey A.J. Delivery of drugs by the pulmonary route. Rhodes C.T., Banker G.S. Modern Pharmaceutics. 2002;479-499 Marcel Dekker, New York.
29. Nielsen K.G., Skov M., Klug B., Ifversen M., Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from the aerolizer. 10:1997;2105-2109.
30. Chodosh S., Flanders J.S., Kesten S., Serby C.W., Hochrainer D., Witek J.T.J. Effective delivery of particles with the handihaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. 14:2001;309-315.
31. Warren S., Taylor G., Smith J., Buck H., Parry-Billings M. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. 15:2002;15-25.
32. T.M. Crowder, M.D. Louey, V.V. Sethuraman, H.D.C. Smyth, A.J. Hickey, 2001:An odyssey in inhaler formulations and design, 25 (2001) 99-113.
33. J. Peart, M.J. Clarke, Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler, Fall (2001).
34. Hill M. Characteristics of an active multiple-dose dry powder inhaler. Byron P.R., Dalby R.N., Farr S.J. Respiratory Drug Delivery IV. 1994;Interpharm Press, Buffalo Grove, IL. 109-116.
35. Patton J.S. Deep-lung delivery of therapeutic proteins. 27:1997;34-38.
36. A.J. Hickey, T.M. Crowder, Dry powder inhaler devices: multidose dry powder drug packages, controlled systems, and associated methods, PCT W001/68169 2001.
37. L. DeYoung, The AeroDose multidose inhaler device design and delivery characteristics, Respiratory Drug Delivery VI, Hilton Head, FL, 1998.
38. x. Dalby R.N., Byron P.R., Farr S.J. Respiratory Drug Delivery VI. 1998;83-90 Interpharm Press, Buffalo Grove, IL.
39. Newman S.P., Steed K.P., Reader S.J., Hooper G., Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. 85:1996;960-964.
40. J.Y. Ding, K.S. Blythe, W.C. Zimlich, B.D. McVeety, M.E. Placke, A.R. Imondi, Delivery of a chemotherapy agent for cancer treatment via nebulization, Respiratory Drug Delivery VIII, Tucson, AR, 2002.
41. Barnes P.J. New Drugs For Asthma. 1989;VCH Publishers, New York, NY.
42. Kaliner M.A., Barnes P.J., Persson C.G.A. Asthma, Its Pathology and Treatment. 1991;Marcel Dekker, New York, NY.
43. Nyce J.W., Leonard S.A., Gillum A.M. Respirable antisense oligonucleotides (RASON's): formulation and delivery in theory and practice. Dalby R.N., Byron P.R., Farr S.J., Peart J. Respiratory Drug Delivery VII. 2000;13-17 Serentec Press, Inc, Raleigh, NC.
44. Mullen P.D., Mullen L.R. Implementing asthma self-management education in medical care settings - issues and strategies. 72:1983;611-622.
45. Garcia-Contreras L., Sarubbi D., Flanders E., O'Toole D., Smart J., Newcomer C., Hickey A.J. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. 18:2001;1685-1693.
46. Suarez S., Garcia-Contreras L., Sarubbi D., Flanders E., O'Toole D., Smart J., Hickey A.J. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. 18:2001;1677-1684.
47. Okumura K., Iwakawa S., Yoshida T., Seki T., Komada F. Intratracheal delivery of insulin. Absorption from solution and aerosol by rat lung. 88:1992;63-73.
48. Pohl R., Muggenburg B.A., Wilson B.R., Woods R.J., Burrell B.E., Steiner S.S. A dog model as a predictor of the temporal properties of pulmonary Technosphere™/insulin in humans. Dalby R.N., Byron P.R., Farr S.J., Peart J. Respiratory Drug Delivery VII. Vol. II:2000;463-466 Serentec Press, Raleigh, NC.
49. L. Garcia-Contreras, T. Morcol, S.D. Bell, A.J. Hickey, Evaluation of novel particles as pulmonary delivery systems for insulin in rats, (in press).
50. T. Scott, L. Brown, K. Hogeland, R. Proos, Y. Qin, J. Rashba-Step, A. Sullivan, L. Wagner, ProMaxx novel protein matrix microspheres for therapeutic protein delivery, 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, CA, 2001.
51. Davis D.S. Scand. J. Respiratory Disease. 103:(Suppl.):1975;44-49.